reports
Moody's announces completion of a periodic review of ratings of Biogen...
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Biogen Inc.. Global Credit Research- 10 Nov 2021. New York, November 10, 2021-- Moody's Investors Service has completed a periodic review of the ratings of Biogen Inc. and other ratings that are associated with the same analytical unit.
Moody's affirms Biogen at Baa1; revises outlook to negative
Rating Action: Moody's affirms Biogen at Baa1; revises outlook to negative. Global Credit Research- 10 Nov 2021. New York, November 10, 2021-- Moody's Investors Service affirmed the ratings of Biogen Inc. including the Baa1 senior unsecured rating.
Moody's assign's Baa1 to Biogen's notes; on review for downgrade
Rating Action: Moody's assign's Baa1 to Biogen's notes; on review for downgrade. Global Credit Research- 04 Feb 2021. New York, February 04, 2021-- Moody's Investors Service assigned a Baa1 rating to the new senior unsecured notes being issued by Biogen Inc. that will be offered in exchange for a series of existing notes.
Moody's announces completion of a periodic review of ratings of Biogen...
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Biogen Inc.. Global Credit Research- 15 Dec 2020. New York, December 15, 2020-- Moody's Investors Service has completed a periodic review of the ratings of Biogen Inc. and other ratings that are associated with the same analytical unit.
Moody's affirms Biogen at Baa1; outlook revised to negative
Rating Action: Moody's affirms Biogen at Baa1; outlook revised to negative. Global Credit Research- 28 Sep 2020. New York, September 28, 2020-- Moody's Investors Service affirmed the ratings of Biogen Inc. including the Baa1 senior unsecured rating.
Moody's: Tecfidera patent ruling credit negative for Biogen
Announcement: Moody's: Tecfidera patent ruling credit negative for Biogen. Global Credit Research- 18 Jun 2020. New York, June 18, 2020-- Moody's Investors Service commented that the recent patent ruling by a federal court in West Virginia related to the multiple sclerosis drug Tecfidera is credit negative for Biogen, Inc. This is because of increased uncertainty related to generic competition in the US occurring before 2028. Biogen will appeal the ruling, and Moody's does not...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.